If you’re retired and looking for your investment portfolio to provide an income stream, the biggest thing you’re looking for is consistency. And that’s what you’ll get from quality monthly dividend stocks. Unlike a dividend stock that pays out quarterly, annually or irregularly, monthly dividend stocks provide retirees with a consistent cash flow to help
Bargain stocks are making a comeback, as growth stocks are now seen as a bubble on the brink of bursting. Amid this shift, value stocks are attractive bets, offering healthy long-term upside and an income stream at attractive prices. These stocks, overshadowed in a market dazzled by high-fliers, present a unique opportunity for diversification and
Steel prices are trading under pressure in 2024 with VanEck Steel ETF (NYSEARCA:SLX) down about 4% year-to-date. This has promoted commodity investors to draw a list of stocks to avoid in this space.  The latest data shows that China’s crude steel output remained unchanged in 2023 compared to the previous year, marking a stabilization after
The Magnificent 7 stocks – Apple (NASDAQ:AAPL), Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT), Amazon.com (NASDAQ:AMZN), Meta Platforms (NASDAQ:META), Tesla (NASDAQ:TSLA) and Nvidia (NASDAQ:NVDA) – have been the darlings of Wall Street for the past few years. And for good reason – they have dominated their markets and delivered outstanding returns for investors. However, their meteoric rise
Both Advanced Micro Devices (NASDAQ:AMD) stock and Nvidia (NASDAQ:NVDA) have each hit their respective highs in the past year with AMD being up 115% and NVDA 236% over the past year. This has been to due the massive innovation taking place over the past year with the growth of AI.  However, AMD stock does not
Palantir Technologies (NYSE:PLTR) initially focused on serving the defense and intelligence sectors but has since expanded its customer base to include various industries such as healthcare, energy, and finance. The company has made impressive strides to improve profitability, and the new AI platform rolled out last year is accelerating top-line growth. As a result, there are
After witnessing some of the hottest software stocks skyrocket to dizzying valuations over the past few years, many investors wonder if opportunities remain in this high-flying sector. With sales multiples stretching well into the double digits for companies like Snowflake (NYSE:SNOW) and Datadog (NASDAQ:DDOG), I believe the easy money has already been made. Many of
Small-cap value stocks stand out as one of the top ways to anchor a long-term portfolio. We all know that small-caps outperform their large-cap cousins over a sufficiently long horizon. The reasoning is obvious – small-caps have more room to grow than bigger stocks, and given enough time, their growth compounds more than mega-caps. But
Cloud AI combines the power of artificial intelligence with the power of cloud computing. That combination offers significant benefits to businesses of all sizes. Those competitive advantages make cloud AI stocks potentially much more valuable. Better, research firms believe that compound annual growth rates over the next 5 years will approach 40% for cloud AI.
Speculative investors are willing to invest in stocks that many investors would steer clear from. That’s been the case with EV charging stocks. The sector has been beaten down alongside electric vehicle stocks. The electric vehicle (EV) transition is underway. But it’s taking longer than some consumers want and many investors expected. However, at least
The investing landscape can be daunting, and this is where steady growth stocks come in. Investors often find themselves chasing up-and-coming stocks, instead of investing in high quality growth companies.  They will often ask “what is the next Tesla (NASDAQ:TSLA) or Nvidia (NASDAQ:NVDA)?” While this isn’t necessarily a bad thing, it can lead to both
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech